TARGETING CGRP FOR MIGRAINE TREATMENT: A NEW ERA

Authors

M. Vikelis
M. Rapoport

Keywords:

Calcitonin gene-related peptide (CGRP), Monoclonal antibodies, Headache treatment, Neuromodulation, Neurostimulation, Magnetic stimulation, Headache devices

Abstract

The introduction of treatments blocking calcitonin gene-related peptide (CGRP) or its receptor is anticipated to begin a new era in migraine treatment. Monoclonal antibodies shall be used as migraine preventives and small molecules as acute treatment for migraine attacks, offering targeted but, more importantly, safe therapeutic choices for our migraine patients.